The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISA 2020 | The evolution of AL amyloidosis therapy
Many therapies for AL amyloidosis are derived from treatments commonly used for multiple myeloma, with initial trials investigating melphalan and prednisone. In this video Joel Buxbaum, MD, Scripps Research, La Jolla, CA, tells us about the evolution of AL amyloidosis therapy, delineating the trend of regimens that parallel that of multiple myeloma and commenting on alternative therapies such as TUDCA, doxycycline and epigallocatechin-3-gallate. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
